Venus Remedies

Venus Remedies Interest Coverage

The Interest Coverage Ratio of Venus Remedies (VENUSREM.NS) as of Nov 10, 2026 is 3.69. In the previous year, Interest Coverage Ratio was 4.23 — a change of -12.70% (lower).

Interest Coverage

3.69

YoY

-12.70%

Last updated:

Interest Coverage Ratio of Venus Remedies is 2025 3.69 . Interest Coverage Ratio of Venus Remedies was 2024 4.23 . It decreases by -12.70% lower compared to the previous year.

The Venus Remedies Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2018
0.19 INR
Jan 1, 2019
-0.29 INR
Jan 1, 2020
0.96 INR
Jan 1, 2021
3.41 INR
Jan 1, 2022
71.78 INR
Jan 1, 2023
4.19 INR
Jan 1, 2024
4.23 INR
Jan 1, 2025
3.69 INR
The Venus Remedies Interest Coverage history
YEARInterest CoverageYoY
3.69-12.70%
4.23+0.84%
4.19-94.16%
71.78+2,005.42%
3.41+255.59%
0.96-428.22%
-0.29-256.36%
0.19+42.47%
0.13+32.69%
0.10+38.56%
0.07-97.61%
2.98—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Venus Remedies Stock analysis

What does Venus Remedies do? Venus Remedies Ltd. manufactures and trades pharmaceutical products, focusing on injectables, tablets, and topical preparations for therapeutic segments including anti-infective, oncology, skin and wound care, and pain management. The company's brands such as Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, Ventaful, and Nervolize cater to critical care and super specialty markets. Its product portfolio addresses antimicrobial resistance (AMR), oncology, neurology, anticoagulants, and herbal solutions, serving medicine, surgery, neuro, and orthopedics. The firm operates in the Pharmaceutical Formulation segment with three manufacturing facilities. The company sells its pharmaceutical products to healthcare providers and institutions globally, targeting critical care and super specialty segments. Brands like Potentox and Vancoplus Combi are positioned for antimicrobial resistance (AMR) solutions, while Neurotol and Trois serve neurology and orthopedics. Supime and Zydotum focus on pain management and skin care, and Septiloc and Mucomelt address anticoagulants and wound care. Venus Remedies' formulations include injectables, tablets, and topical preparations for diverse therapeutic needs. Venus Remedies Ltd. generates revenue through the sale of its branded pharmaceutical products, including injectables, tablets, and topical preparations. The company's product lines target specific therapy areas such as AMR, oncology, skin and wound care, and pain management, with brands like Ventaful and Nervolize supporting neurology and anticoagulant markets. The firm's global reach in injectable manufacturing and focus on super specialty segments drive its market positioning within the Pharmaceutical Formulation segment. Venus Remedies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Venus Remedies stock

Interest Coverage Ratio of Venus Remedies is 3.69 in 2025.

Interest Coverage Ratio of Venus Remedies changed from 4.23 to 3.69, representing a -12.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Venus Remedies since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Venus Remedies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Venus Remedies

All Key Metrics — Venus Remedies